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BACKGROUND Pre-clinical data show that overlapping scaffold seg-
ments show delayed healing and strut coverage compared to non-
overlapping scaffold segments. Little is known whether this may have
an impact on clinical outcome.
METHODS Within the ABSORB-EXTEND study of 812 patients with 1
year follow-up complete, patients with overlapping scaffolds (n¼115)
were compared to patients with non-overlapping scaffolds (n¼697).
RESULTS No differences in baseline patient and lesion characteristics
between both patient groups were noted, apart from the signiﬁcant
longer lesion length in the overlapping scaffold group (16.77.3 versus
11.64.4 mm, [p<0.0001; 95% CI: 3.7-6.4]) and subsequently less
lesion type B1 and more B2. Furthermore, more patients were treated
for stable angina in the overlapping scaffold group (72% versus 54%,
p¼0.0003). In the overlapping scaffold group 41/125 (33%) lesions
were > 20 mm long, compared to 33/734 (5%) lesions in the non-
overlapping group, p<0.0001. The 1 year clinical outcome is summa-
rized in the table below. Scaffold Thrombosis is reported according
ARC and Myocardial Infarction according protocol deﬁnitions.Overlapping Non-overlapping P valueCardiac death 0.9% 0.7% 0.6Myocardial Infarction (MI) 8.7% 2.4% 0.002- Q wave MI 1.7% 0.9% 0.3- non-Q wave MI 7.0% 1.6% 0.003Target Lesion Revascularization 0.9% 2.6% 0.5Def/Prob Scaffold Thrombosis (ST) 1.8% 0.9% 0.3- Early Def/Prob ST 1.7% 0.4% 0.1- Late Def/Prob ST 0.0% 0.4% 1.0CONCLUSIONS In the non to moderate complex lesion population of
ABSORB-EXTEND, patients with overlapping scaffolds showed only
signiﬁcantly more non-Q wave myocardial infarctions compared to
the non-overlapping scaffold group. This difference occurred mainly
in-hospital and was procedure related.
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BACKGROUND The DESolve Novolimus Eluting Bioresorbable Cor-
onary Scaffold System (NEBCSS) is a drug-eluting bioresorbable scaf-
fold combining a PLLA-based scaffold coated with Novolimus, a
macrocyclic lactone mTOR inhibitor with potent anti-proliferative
properties. The drug dose is 5 mg per mm of scaffold length; the device
is available in multiple diameters (2.5 – 3.5 mm) and lengths (14, 18
and 28 mm). The DESolve Nx study is multi-center evaluation of the
safety and efﬁcacy of the DESolve NEBCSS in patients with single, de
novo, native coronary artery lesions.METHODS A total of 126 patients were enrolled in this prospective
registry. Patients receiving the study device were analyzed for mul-
tiple clinical endpoints including: device and procedure success;
Major Adverse Cardiac Events (MACE), a composite endpoint of car-
diac death, target vessel MI, or clinically-indicated target lesion
revascularization (CI-TLR); Target Vessel Revascularization, (CI-TVR)
and stent thrombosis assessed at 1, 6 and annually to 5 years. All
patients underwent angiographic assessment at 6 months and a sub-
set of patients underwent IVUS and OCT assessment also at 6 months
and imaging 12 months using multislice computed tomography
(MSCT). Additionally, at single centers, multi-modality imaging was
completed at 18 months and 3 years.
RESULTS Mean age at baseline was 62 years, 32% were females, and
21% diabetics. Lesion length was 11.2 mm, RVD was 3.06 mm, and
18.3% showed moderate-to-heavy calciﬁcation. Six-month QCA
demonstrated low mean in-scaffold late lumen loss (0.20 mm), 18.3%
DS and an MLD of 2.45 mm. Serial IVUS at baseline and 6 months
demonstrated a signiﬁcant increase in mean lumen (D 10.0%,
p ¼ < 0.001) and scaffold areas (D 15.7%, p ¼ < 0.001) and low %
volume obstruction (5.1%). Serial OCT demonstrated a signiﬁcant in-
crease in scaffold area (D 16.9 %, p ¼ < 0.001) with 98.8% neointimal
coverage of the scaffold at 6 months. Twelve-month MSCT results
demonstrated lumen dimension maintenance from 6 to 12 months.
QCA at 18 months shows minimal lumen change and 3 year OCT im-
aging reveals the “golden tube” indicating resorption of the scaffold.
Clinical events remained low (MACE ¼ 5.69% and 7.4% at 12 and
24 months respectively) with no reports of deﬁnite stent thrombosis.
CONCLUSIONS DESolve demonstrated safety and efﬁcacy with low late
lumen loss. Serial imaging assessments indicatedearlyvessel restorationat
6 months with good luminal patency at 12 months by MSCT. At 12 and 24
months, the clinical event rates remain low. Imaging endpoints at 18
months and 3 years and 3-year clinical results will be presented.
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BACKGROUND The SYNTAX revascularization index (SRI), representing
the percentage of revascularized myocardium, has been shown to be a
strong independent predictor of adverse ischemic events after percuta-
neous coronary intervention (PCI); however, its predictive capability
among patients with complex coronary artery disease (CAD) undergoing
PCI with second-generation everolimus-eluting stents (EES) remains un-
explored. We sought to evaluate the impact of incomplete revasculariza-
tion as assessed by the SRI on 2-year adverse ischemic events in a
population of patients with complex CAD undergoing EES-PCI.
METHODS Among 1900 patients enrolled in A Registry to Evaluate
Safety and Effectiveness of Everolimus Drug Eluting Stent for Coro-
nary Revascularization (SEEDS), SRI was available in 1851. Patients
were stratiﬁed into three groups (SRI¼100%, SRI 50 to 99%, and SRI
<50%), according to the proportion of revascularized myocardium.
Mortality and major adverse cardiac events (MACE) were compared
between groups.
